AMBULANTE KOLOSKOPIE BEI COLITIS ULCEROSA UND KOLOREKTALEM KARZINOM = COLOSCOPIE AMBULATOIRE DANS LA COLITE ULCEREUSE ET LE CANCER COLORECTALTHEUER D.1981; FORTSCHR. MED.; ISSN 0015-8178; DEU; DA. 1981; VOL. 99; NO 6; PP. 171-174; ABS. ENG; BIBL. 20 REF.Article

ZUM WANDEL DER LAPAROSKOPIEINDIKATION = LE CHOIX DE L'INDICATION DE LA LAPAROSCOPIETHEUER D; NATUSCH R.1973; DTSCHE GESUNDH.-WES.; DTSCH.; DA. 1973; VOL. 28; NO 1; PP. 9-12; ABS. RUSSE ANGL.; BIBL. 22REF.Serial Issue

AUSTRALIA-ANTIGEN (AU/SH/HAA)-BEFUNDE BEI CHRONISCHEN LEBERERKRANKUNGEN = L'ANTIGENE AUSTRALIE (AU/SH/HAA), DANS LES MALADIES HEPATIQUES CHRONIQUESWAGNER K; GESERICK G; SCHIMMELPFENNIG W et al.1972; DTSCHE GESUNDH.-WES.; DTSCH.; DA. 1972; VOL. 27; NO 50; PP. 2364-2367; ABS. RUSSE ANGL.; BIBL. 72 REF.Serial Issue

Pathologie der Leber-zirrhose und der portalen Hypertension = Pathology of liver cirrhosis and portal hypertensionBLÄKER, H; THEUER, D; OTTO, H. F et al.Der Radiologe (Berlin. Print). 2001, Vol 41, Num 10, pp 833-839, issn 0033-832XArticle

Pathohistologische Befunde bei Lebermetastasen : Lebermetastasen = Pathohistologic findings in liver metastases : Liver metastasesBLÄKER, H; HOFMANN, W. J; THEUER, D et al.Der Radiologe (Berlin. Print). 2001, Vol 41, Num 1, pp 1-7, issn 0033-832XArticle

Solid-phase competitive luminescence immunoassay for lysozyme in faecesPING GAO; JOHN, M. R; SCHMIDT-GAYK, H et al.Clinica chimica acta. 1995, Vol 239, Num 2, pp 167-177, issn 0009-8981Article

Interferon β-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating studyNIKOLAUS, S; RUTGEERTS, P; FEDORAK, R et al.Gut. 2003, Vol 52, Num 9, pp 1286-1290, issn 0017-5749, 5 p.Article

Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trialFEURLE, G. E; THEUER, D; VELASCO, S et al.Gut. 1989, Vol 30, Num 10, pp 1354-1361, issn 0017-5749Article

Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitisKRUIS, W; JUDMAIER, G; KAYASSEH, L et al.European journal of gastroenterology & hepatology. 1995, Vol 7, Num 5, pp 391-396, issn 0954-691XArticle

Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapsesKRUIS, W; SCHREIBER, S; STOLTE, M et al.Gut. 2001, Vol 49, Num 6, pp 783-789, issn 0017-5749Article

Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitisKRUIS, W; BRANDES, J.-W; SCHREIBER, S et al.Alimentary pharmacology & therapeutics. 1998, Vol 12, Num 8, pp 707-715, issn 0269-2813Article

Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16CURRAN, M. E; LAU, K. F; VAN DEVENTER, S. J. H et al.Gastroenterology (New York, NY. 1943). 1998, Vol 115, Num 5, pp 1066-1071, issn 0016-5085Article